LAVA Therapeutics N.V. (NASDAQ: LVTX) has entered a definitive share purchase agreement whereby XOMA Royalty will acquire LAVA for (i) between $1.16 and $1.24 per share in cash, consisting of (A) USD $1.16 in cash per ordinary LAVA share, plus (B) an additional amount of cash of up to $0.08 per ordinary LAVA share, plus (ii) a non-transferable contingent value right per ordinary LAVA share representing the right to receive 75% of the net proceeds related to LAVA’s two partnered assets and 75% of any net proceeds from any out license or sale of LAVA’s unpartnered programs.
“We congratulate our long-standing client LAVA Therapeutics N.V. with their acquisition by XOMA Royalty Corporation. It’s a pleasure supporting them on this journey, alongside Cooley, and we look forward to seeing what the future holds for both companies”
LAVA Therapeutics N.V.
LAVA Therapeutics N.V. is a biopharmaceutical company that has developed several clinical-stage bispecific gamma delta T cell engagers using its proprietary Gammabody® platform, including JNJ-89853413, targeting CD33 and hematologic cancers (NCT06618001), partnered with Johnson & Johnson, and PF-08046052, targeting EGFR and solid tumors (NCT05983133), partnered with Pfizer, Inc. For more information on LAVA, please visit www.lavatherapeutics.com. Gammabody® is a registered trademark of LAVA Therapeutics N.V.
The NautaDutilh team was led by Paul van der Bijl with invaluable support from Willem Bijveld, Joppe Schoute, Esther Schreiber, and Eline Keuning.